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Abstract
Recent mathematical models have been developed to study the dynamics of chronic myelogenous leukemia (CML) under
imatinib treatment. None of these models incorporates the anti-leukemia immune response. Recent experimental data
show that imatinib treatment may promote the development of anti-leukemia immune responses as patients enter
remission. Using these experimental data we develop a mathematical model to gain insights into the dynamics and
potential impact of the resulting anti-leukemia immune response on CML. We model the immune response using a system
of delay differential equations, where the delay term accounts for the duration of cell division. The mathematical model
suggests that anti-leukemia T cell responses may play a critical role in maintaining CML patients in remission under imatinib
therapy. Furthermore, it proposes a novel concept of an ‘‘optimal load zone’’ for leukemic cells in which the anti-leukemia
immune response is most effective. Imatinib therapy may drive leukemic cell populations to enter and fall below this
optimal load zone too rapidly to sustain the anti-leukemia T cell response. As a potential therapeutic strategy, the model
shows that vaccination approaches in combination with imatinib therapy may optimally sustain the anti-leukemia T cell
response to potentially eradicate residual leukemic cells for a durable cure of CML. The approach presented in this paper
accounts for the role of the anti-leukemia specific immune response in the dynamics of CML. By combining experimental
data and mathematical models, we demonstrate that persistence of anti-leukemia T cells even at low levels seems to
prevent the leukemia from relapsing (for at least 50 months). As a consequence, we hypothesize that anti-leukemia T cell
responses may help maintain remission under imatinib therapy. The mathematical model together with the new
experimental data imply that there may be a feasible, low-risk, clinical approach to enhancing the effects of imatinib
treatment.
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Introduction
Chronic myelogenous leukemia (CML) results from the
uncontrolled growth of white blood cells due to up-regulation of
the abl tyrosine kinase [1]. The standard first-line therapy against
CML is imatinib, a molecular-targeted drug that inhibits the abl
tyrosine kinase [2]. Under imatinib, nearly all patients attain
hematologic remission (HR) [3] and 75% achieve cytogenetic
remission (CR) [4]. However, imatinib does not completely
eliminate residual leukemia cells and patients inevitably relapse
after stopping treatment [4]. We note that for a hematologic
remission (also known as complete hematologic response) the
following must be present: Platelet count 450,000/mL, WBC count
,10,000/mL, WBC differential: no immature granulocytes and
,5% basophils, Spleen nonpalpable. Cytogenetic remission (or
response) is defined with the following sub-categories. None: Ph+
cells .95%; Minimal: Ph+ cells 66–95%; Minor: Ph+ cells 36–
65%; Partial: Ph+ cells 1–35%; Complete: Ph+ cells 0%.
In this paper, we model the dynamics of T cell responses to
CML. Insights gained from this model were used to develop a
possible combination between imatinib and immunotherapy, in
the form of cancer vaccines, to enhance the efficacy of imatinib
treatment and potentially eliminate leukemia for a durable cure.
Various papers have proposed hypotheses concerning the effects
of imatinib treatment on leukemia cells from a dynamical systems
perspective. In a recent work, Michor et al. develop a model for the
interaction between leukemia and imatinib [5]. In their model,
they assume that leukemia cells differentiate through four stages of
their life cycle, beginning with leukemia stem cells. Imatinib
functions by reducing the rate at which leukemia cells pass from
one stage to the next, causing a rapid drop in the leukemia
population. Based on their assumptions and analysis, they propose
that leukemia inevitably persists, because imatinib hinders the
differentiation of differentiated leukemia cells, but does not affect the
leukemiastemcells.Inparticular,Michoretal.hypothesizethatthere
is always a steadily growing population of leukemia stem cells despite
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population under imatinib eventually relapses, regardless of whether
the model considers imatinib resistance mutations.
In a subsequent paper [6], Roeder et al. develop a similar model
of CML and imatinib. However, they subdivide the leukemia stem
cells into two compartments: proliferating and quiescent cells.
Proliferating leukemia stem cells are affected by imatinib, while
quiescent leukemia stem cells are not affected. Due to this
additional assumption, the leukemia population under imatinib
does not relapse without the effects of imatinib resistance
mutations. Instead, under imatinib treatment, the leukemia stem
cell population restabilizes at lower equilibrium level and does not
continue growing as in the Michor model.
Both [5] and [6] propose that imatinib does not eliminate the
leukemia stem cell population. Consequently, the papers conclude
that imatinib therapy should be combined with an additional
treatment that either directly impacts leukemia stem cells or causes
leukemia stem cells to become vulnerable to imatinib.
As an alternative approach, Komorova and Wodarz develop a
model that focuses on the drug resistance of leukemia cells [7]. In
their model, they implicitly assume that imatinib affects all leukemia
cells including stem cells and that inevitable relapse is a result of
acquired imatinib resistance mutations. Komorova and Wodarz
consider the possibility of treating patients with multiple drugs to
reduce the probability of any leukemia cell eventually acquiring
resistance-mutations to all drugs. They determine that a treatment
strategy consisting of three leukemia-targeted drugs of different
specificity might have a strong chance of eliminating the disease.
The three approaches discussed above present a variety of
hypotheses for the dynamics of imatinib treatment on leukemia
cells. These papers also propose potential treatment strategies to
enhance the effectiveness of imatinib. However, the difficulty with
these treatments is that it is unclear what kind of drug could be
used to target leukemia stem cells or what alternative drugs could
be used in addition to imatinib for a multiple-drug strategy.
In this paper, we model the anti-leukemia immune response in
CML patients on imatinib therapy. Biological insights from the
model lead us to propose a novel approach that incorporates the
leukemia specific immune response into the mathematical models.
We show that the model of Michor et al. [5], when extended in
time, predicts a relapse approximately three years after the start of
treatment. However, a three-year relapse conflicts with clinical
observations as patients under imatinib often remain in cytoge-
netic remission for several years. The models of Roeder et al. and
Komorova and Wodarz present alternative models that may
explain the long-term remission typically observed in patients;
however, none of these approaches consider the dynamics and
impact of the immune response to CML.
Recent experiments by Chen et al., observe that some CML
patients under imatinib-induced remission develop a robust but
transient anti-leukemia immune response involving both CD4+
and CD8+ T cells [8]. The results of Chen et al. extend the findings
of Wang et al. pertaining to antigen-presenting cells and CD4+ T
cells in CML [9]. By developing a model that combines imatinib
and immune dynamics, we formulate an alternative hypothesis
about how remission is sustained and propose a novel treatment
strategy to enhance the effectiveness of imatinib.
The paper is organized as follows. In the Materials and Methods
section we develop a mathematical model for the dynamics of
CML, imatinib, and the imatinib-induced immune response to
CML. This model is written as a system of delay differential
equations (DDEs) where the delay accounts for T cell division. As
part of the model presentation, we pay considerable attention to
discussing the parameter estimates. This discussion is divided into
two parts. First we deal with the estimation of the universal
parameters, i.e., the parameters for which we assume that their
range is identical for all patients. We then proceed to discuss the
estimation of the three patient specific parameters. This estimation
is done by fitting the simulations of the model to the experimental
data from [8].
In the Results section we use simulations of our model to discuss
the brief anti-leukemia immune response that occurs during
imatinib-induced remission. We hypothesize that the immune
response serves to sustain leukemia remission longer than it would
last otherwise. At the same time, we do point out that this immune
response dies off too quickly to be effective at completely
eliminating CML.
The work of [8] has also indicated that when an anti-leukemia
immuneresponseisnot detectable,itcan bere-stimulated byinvitro
incubation with irradiated autologous leukemia cells or lysates
(available fromcryopreserved blood fromthepatientbeforeimatinib
therapy). We hypothesize that a similar stimulation of the anti-
leukemia immune response can be also obtained in-vivo. We refer to
such a procedure as a ‘‘cancer vaccine’’. We modify our
mathematical model to include terms that account for the cancer
vaccines. Through mathematical simulations of this new model we
show that if indeed a similar response to what was seen in vitro can
be also obtained in patients, one can possibly use properly timed
vaccines to develop an anti-leukemia response that will be of
sufficient magnitude and duration to eradicate all residual leukemia
cells. The timing of the vaccine and the doses are tailored to the
specific measurable parameters of the immune response of each
patient. We study the number of vaccines, their doses, and their
timing. We also study the sensitivity of the model to the patient
specific parameters. Comments on various aspects of the proposed
treatmentstrategyareprovidedintheconcludingDiscussionsection.
Materials and Methods
A Mathematical Model of the Immune Response to CML
In [8] Chen et al. conducted an experimental study involving
fourteen patients under imatinib treatment. During the course of
Author Summary
Recent mathematical models have been developed to
study the dynamics of chronic myelogenous leukemia
(CML) under imatinib treatment. None of these models
incorporates the anti-leukemia immune response. Recent
experimental data show that imatinib treatment may
promote the development of anti-leukemia immune
responses as patients enter remission. Using these
experimental data, we developed a mathematical model
to gain insights into the dynamics and potential impact of
the resulting anti-leukemia immune response on CML. The
mathematical model suggests that anti-leukemia T cell
responses may play a critical role in maintaining CML
patients in remission under imatinib therapy. Furthermore,
it proposes a novel concept of an ‘‘optimal load zone’’ for
leukemic cells in which the anti-leukemia immune
response is most effective. Imatinib therapy may drive
leukemic cell populations to enter and fall below this
optimal load zone too rapidly to sustain the anti-leukemia
T cell response. As a potential therapeutic strategy, the
model shows that vaccination approaches in combination
with imatinib therapy may optimally sustain the anti-
leukemia T cell response to potentially eradicate residual
leukemic cells for a durable cure of CML.
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time points to measure the evolution of the anti-leukemia T cell
responses of each patient. All patients achieved HR within 1–3
months. Ten patients achieved complete CR, and 4 achieved
major CR. All patients also achieved at least major molecular
responses, and sustained molecular as well as cytogenetic responses
over time (up to 60 months), except patient 9 (P9), who relapsed
after 3 years, and P13, who relapsed after 4 years (after stopping
treatment due to imatinib intolerance). We note that a complete
molecular response is when the BCR-ABL transcript is non-
detectable and non-quantifiable. A major molecular response is
defined as BCR-ABL/control gene ratio 0.001.
To study the dynamics of the imatinib-induced immune response,
we formulate a mathematical model for leukemia cells and anti-
leukemia T cells. The leukemia growth and the response to imatinib
follows [5] to which we add interactions with anti-leukemia T cells.
Leukemia cells may be killed by interactions with T cells. Also, T
cells interacting with leukemia cells may be stimulated to proliferate
orto becomeanergic and die. The T cellinteractions are modeled in
the same way as in our previous paper [10].
The mathematical model is formulated as a system of DDEs as
follows:
_ y y0~ ry 1{u ðÞ {d0
  
y0{qCpC ,T ðÞ y0,
_ y y1~ayy0{d1y1{qCpC ,T ðÞ y1,
_ y y2~byy1{d2y2{qCpC ,T ðÞ y2,
_ y y3~cyy2{d3y3{qCpC ,T ðÞ y3,
_ z z0~ rz{d0 ðÞ z0zryy0u{qCpC ,T ðÞ z0,
_ z z1~azz0{d1z1{qCpC ,T ðÞ z1,
_ z z2~bzz1{d2z2{qCpC ,T ðÞ z2,
_ z z3~czz2{d3z3{qCpC ,T ðÞ z3,
ð1Þ
_ T T~sT{dTT{pC ,T ðÞ Cz2npC nt,Tnt ðÞ qTCnt, ð2Þ
where
pC ,T ðÞ ~p0e{cnCkT, C~
P 3
i~0
yiz
P 3
i~0
zi,
Cnt~Ct {nt ðÞ , Tnt~Tt {nt ðÞ :
A state diagram that corresponds to Equations 1 and 2 is shown
in Figure 1. The system of Equation 1 is a modification of the
model of [5] for which in each question we added a term that
accounts for the death of leukemic cells as a result of an interaction
with T cells. The variables y0, y1, y2, and y3 denote the concentra-
tions of leukemia hematopoietic stem cells (SC), progenitors (PC),
differentiated cells (DC), and terminally differentiated cells (TC)
without resistance mutations to imatinib. The variables z0, z1, z2,
and z3 denote the respective concentrations of leukemia cells with
resistance mutations. The rate constants a, b, and c are given with
indices corresponding to non-resistant and resistant leukemia
populations. The death rates of the four cell categories are given
by d0, d1, d2, and d3, respectively. The constant u is the rate of
resistance mutation per cell division.
The variable Cdenotesthetotalconcentration ofall leukemia cells
with and without resistance mutations. The variable T denotes the
concentration of anti-leukemia T cells. The final terms in each of the
equations in Equation 1 are of the form qCp0e{cnCkTyi (or
qCp0e{cnCkTzi). We assume the law of mass action, stating that two
cell populations interact at a rate proportional to the product of their
concentrations. Hence, the component kTyi (or kTzi) is the rate of
interaction between T cells and the leukemia subpopulation yi (or zi)
where k is the kinetic coefficient.
The coefficient p0 is the probability that a T cell engages the
cancer cell upon interaction, and qc is the probability that the cancer
cell dies from the T cell response. Furthermore, leukemia cells
suppress anti-leukemia immune responses, and while the precise
mechanism is unknown, we assume that the level of down-regulation
depends on the current cancer population. In particular, we model
the probability that a T cell engages a cancer cell decays exponen-
tially as a function ofthe cancer concentration, i.e., the probabilityof
a productive T cell interaction with a cancer cell is p0e{cnC where cn
is the rate of exponential decay due to negative pressure.
It is now well established that cancer suppresses the host
immune system in various ways [11]. Leukemia is particularly
immunosuppressive as leukemic cells grow within the bone
marrow, and can directly suppress both growth and function of
normal blood cells. As such, leukemia patients are known to be at
higher risk for infections and other cancers [12,13]. While the
mechanisms are varied, we recently showed that cancer patients
may have a defect in the interferon signaling pathway [14].
Interferon is an important cytokine in driving immune responses.
In Equation 2, sT denotes the constant supply rate of T cells into
the system from stem cells. The second term is the natural death
rate of T cells. The third term is the rate at which T cells engage
leukemia cells and commit to n rounds of division. The final term
represents the population increase due to n divisions of stimulated
T cells where t is the average duration of one division, and Cnt and
Tnt are the time delayed cancer and T cell concentrations
respectively. The coefficient qT is the probability that a T cell
survives the encounter with an activated leukemia cell.
The method of modeling T cell proliferation in Equation 2 is
similar to what we have previously used in [10]. Once a T cell is
stimulated, it exits the collection of interacting T cells and reenters
the system nt time units later after n divisions. This approach
ensures that the T cell population does not double faster than once
Figure1.AStatediagramforthemodelinEquations2and3.(A)Cancercells.Theparametersay,by,cycorrespondtotheratesofdifferentiationof
leukemia cells without imatinib treatment, whereas the parameters a0
y, b0
y, c0
y correspond to the rates of differentiation under imatinib treatment. In the
case of imatinib-resistant cancer cells, the growth and differentiation rates in the diagram are replaced by rzaz, bz, cz.( B )Tc e l l s .
doi:10.1371/journal.pcbi.1000095.g001
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expression or other saturating terms.
Parameter Estimates
A considerable amount of effort is devoted to estimating the
parameters that appear in our mathematical model (Equations 1
and 2). The discussion is divided into two parts. First, we present
the methods for estimating the universal parameters, i.e., the
parameters we assume have ranges of values that are similar for all
patients. Following the work of [5] we assume that the time-
dynamics of cancer is universal, i.e., we describe the evolution of
the cancer cells in their various stages of development using
parameters that are assumed to be identical for all patients.
Clearly, there is no reason to believe that the dynamics of cancer is
identical for all patients (as commonly done in mathematical
models). Nevertheless, it does serve, in our case, as a way of
simplifying the computations in addition to a way to connect
between our work and previous works.
We then proceed to describe the methods we used for estimating
the remaining three model parameters. These parameters
characterize the individual immune response. Consequently they
are allowed to vary from patient to patient.
Universal parameters. The values of the parameters
pertaining to the growth, differentiation, and mutation rates of
leukemia cells are taken from [5] without modification. These
parameters are ry, ay, by, cy, rz, a0
y, b0
y, c0
y, az, bz, cz,a n du. The death
rates from [5] correspond to the natural death rates of the leukemia
populations under imatinib. However, in our model, we distinguish
between the natural death rate of leukemia and the death rate due to
the cytotoxic T cell response. Hence, our natural death rates, di,
should be a fraction, l, of the combined death rates estimated in [5].
Determining what fraction l of the leukemia death rates from
[5] result from non-immune versus immune causes is difficult and
requires some assumptions. First, we assume that l is greater than
0.5, so that the anti-leukemia immune response contributes to less
than half of the decline in leukemia under imatinib treatment. Due
to the lack of data on l we set it as l=0.75. A discussion on the
sensitivity of the results to the choice of l will follow.
For the kinetic coefficient k, we use the same value of 1 (k/mL)
21
day
21 which was originally drawn in [10] from the rate constant of
virus elimination in [15]. For T cell-cancer interactions, we apply
the following assumptions from [10]: 20% of the time nothing
happens, and both cells survive and depart; 20% of the time
cancer lives, and the T cell becomes anergic or dysfunctional; 40%
of the time cancer dies, and the T cell survives and moves on; 20%
of the time both cancer and the T cell die. From these
assumptions, we deduce that the probability of any sort of
interaction is p0=0.8, the probability of cancer dying is p0qC=0.6,
and the probability of a T cell surviving is p0qT=0.4. Hence,
qC=0.6/0.8=0.75 and qT=0.4/0.8=0.5.
In [15], Luzyanina et al. estimate that T cell divisions take
between 0.4 to 2 days, and their best fit estimate is 0.6 days. Also,
Janeway estimates that primed T cells divide 2 to 4 times per day
[16], which corresponds to a duration of 0.25 to 0.5 days.
Combining these sources, we conclude that T cell divisions take
between 0.25 and 2 days. Since the anti-leukemia T cells are
emerging from an environment of immune down-regulation, we
assume they divide at the more conservative rate of one division
per day.
A summary of the estimated parameters is provided in Table 1.
Patient-Dependent Parameters. The data from [8] for
three patients, P1, P4, and P12, each consists of at least five time
points per patient. Hence, we focus on these patients when fitting
the model to patient data. Tables 2–3 summarize the data from [8]
for P1, P4, and P12. Since the duration and the magnitude of the
immune responses vary greatly across the three patients, we fit the
parameters sT, dT, cn, n, y0(0) to each patient independently and do
not attempt to come up with universal estimates of these values.
These five parameters denote the supply rate of anti-leukemia T
cells, the death rate of anti-leukemia T cells, the level of immune
down-regulation by leukemia cells, the average number of T cell
divisions upon stimulation, and the initial concentration of
leukemia stem cells, respectively.
Since even for these three patients only few data points are
available, we do not apply a formal method to fit the five patient-
dependent parameters to the data. Rather, we use certain features
of the data sets, such as the peak height of the T cell response, to
estimate the patient-dependent parameters.
We use known information from the literature to determine
reasonable ranges for n and dT. To determine an upper bound for
the average number of T cell divisions, n, we consider that when
naı ¨ve CD8+ T cells are primed for the first time, they go through
several cycles of division. An analysis of experimental data by
Antia et al. showed that stimulation of naı ¨ve CD8+ cells result with
Table 1. Estimates of universal parameters.
Parameter Description Estimate Source
l Fractional adjustment constant 0.75 Estimate
d0 SC death rate 0.003 l/day [5]
d1 PC death rate 0.008l
d2 DC death rate 0.05l
d3 TC death rate l
ry Growth rate for nonresistant cells 0.008/day [5]
ay Rates without imatinib treatment 1.6
by 10
cy 100
a0
y Rates during imatinib treatment ay/100 [5]
b0
y by/750
c0
y cy
rz Growth rate for resistant cells 0.023/day [5]
az Rates for resistant cells ay
bz by
cz cy
u Mutation rate per division 4610
28/division
K Kinetic coefficient 1 (k/mL)
21 day
21 [10,15]
p0 Prob. T cell engages cancer cell 0.8 [21]
qC Prob. cancer cell dies from
encounter
0.75
qT Prob. T cell survives encounter 0.5
t Duration of one T cell division 1 day [15,16]
doi:10.1371/journal.pcbi.1000095.t001
Table 2. Pre-treatment leukemia load.
Patient P1 P4 P12
Pre-treatment leukemia load (k/mL) 73.0 23.1 116.8
doi:10.1371/journal.pcbi.1000095.t002
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the proliferation of primed CD8+ cells leads to about 10
3 daughter
cells [16], which implies about 10 divisions. Primed CD8+ T cells
continue to divide as long as they receive stimulus, but not as many
times as during the initial stimulation. Hence, we conclude that
primed CD8+ T cells divide fewer than 10 times and most likely
fewer than 8 times per stimulation.
To estimate the range of the T cell death rate, dT, we consider the
observations and calculations from [18] that primed CD4+ Tc e l l s
peak nine days afterstimulation,initially die with a half-life of 3 days,
and slow down to a half-life of 35 days, eight days after the peak of
the response. These numbers yield an initial death rate of 0.23/day
and an eventual death rate of 0.02/day. In addition, in [18] it is
estimated that primed CD8+ T cells die with a half-life of 1.7 days,
yielding a death rate of about 0.4/day. The half-lives of memory
CD4+ and CD8+ T cells are much higher, i.e. 500 days to lifelong
respectively. Since we are looking at data points that were measured
over several years, most of the lingering T cells in the anti-leukemia
response are probably CD4+ effector cells or memory CD4+ and
CD8+ cells. Since we are examining time-scales of several months to
a few years, for convenience, we assume that the T cell death rate is
constant at 0.02/day or lower and do not take into account the
biphasic switch that probably occurs around seventeen days after the
beginning of the immune response.
The characteristics of the five patient-dependent parameters are
summarized in Table 4.
The initial concentration of leukemia stem cells, y0(0), is the
most straightforward parameter to estimate, since its value can be
derived directly from the initial leukemia load measured in [8].
Ifwe assumethat all populationsstartintheirsteadystates,we can
calculate the initial concentrations of all leukemia cell compartments
in terms of y0(0) and the universal parameters given in Table 1.
(Likewise, we can calculate the initial concentration of T cells in
terms of the T cell supply and death rates.)
If we assume that there are no resistant cells at the start of
treatment, the initial concentration of imatinib resistant stem cells
is 0. Note that Michor et al. also consider a scenario, in which the
initial resistant stem cell count is 10 cells [5]. Assuming that an
average person has 6 L of blood, this initial count corresponds to
an initial concentration of 10/6 L,10
29 k/mL. Clearly, this is a
very crude estimate as the leukemic cells are distributed within the
bone marrow, spleen, and blood. However, as will be shown in the
sensitivity study below, the initial concentration plays a rather
limited role in the emerging dynamics, and thus even such a crude
estimate will suffice. See Table 5 for a list of initial concentrations.
To calculate y0(0), we set the pre-treatment leukemia loads listed
in Table 2 equal to the expression for the total initial leukemia
concentration,
P3
i~0 yi 0 ðÞ z
P3
i~0 zi 0 ðÞ , and solve for y0(0).
The T cell death rate, dT, is estimated from the rate of decline of
the anti-leukemia T cell populations after their peak. Hence, the
last three data points for P1, the last five data points for P4, and
the last five data points for P12 are used to estimate the rate of T
cell death dT.
If we assume that the T cell population is at steady state before
treatment, the concentration of anti-leukemia T cells at time 0 is sT/
dT. By setting this ratio equal to the initial T cell concentrations
obtained from the data in Table 3, we can determine sTin terms of dT.
The rate cn of the decay of the immune response due to negative
pressure is difficult to estimate. However, the value of cn affects the
number of T cells that are stimulated during the course of imatinib
treatment and how soon T cell expansion initiates. Specifically, we
can use the data points before the T cell peak to estimate the time
of initiation of the anti-leukemia T cell response for each patient.
Table 3. Patient data from ELISPOT assay from [8] for P1, P4,
and P12.
P1 Time (months) 0 5 30 35 46
SFCs/well 3 29 25 25 9
P4 Time (months) 0 6 9 18 24 32 34 42
SFCs/well 1 16.5 33 30 26 11 15 12
P12 Time (months) 0 2 5 9 13 15 24 30
SFCs/well 11 42 39 71 36.5 43 5 6
SFCs/well for leukemia bearing+remission PBMCs. The measurement for time 0
corresponds to pre-treatment leukemia bearing PBMCs. (See Figure 2 for plots
of the data points.)
doi:10.1371/journal.pcbi.1000095.t003
Table 4. Estimated ranges of patient-dependent parameters.
Parameter Description Estimate Source
n Average number of T cell divisions 1,n,8[ 1 7 ]
dT Anti-leukemia T cell death rate ,0.02/day [18]
sT Anti-leukemia T cell supply rate ? (k/mL)/day Based on dT and patient data
cn Decay rate of immune responsivity ? (k/mL)
21 Based on patient data
y0(0) Initial concentration of leukemia stem cells ? (k/mL) Based on patient data
doi:10.1371/journal.pcbi.1000095.t004
Table 5. Initial concentrations.
Population Value (k/mL) Reason
y0(0) ? Determined by patient data
y1(0) ayy0/d1 Steady state
y2(0) byy1/d2 Steady state
y3(0) cyy2/d3 Steady state
z0(0) 0 or 10
29 Correspond to values in [5]
z1(0) azz0/d1 Steady state
z2(0) bzz1/d2 Steady state
z3(0) czz2/d3 Steady state
Y(0) sT/dT Steady state
doi:10.1371/journal.pcbi.1000095.t005
Dynamics of the Immune Response to CML
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initiate immediately, indicating a lingering immunosuppressive
effect from the leukemia cells. We assume that the T cell responses
start approximately 2.5, 3, and 2 months after the start of imatinib
treatment for patients P1, P4, and P12, respectively.
Given the T cell death rate dT, we can determine the range of
cancer concentrations where the T cell growth rate, p0ke{cnCC,
exceeds the T cell death rate, dT. Before the T cell response starts,
the leukemia concentration falls solely based on its natural death
rate, since there is no active T cell response. Thus, we can further
determine the time that the cancer concentration first reaches the
point where the T cell growth rate exceeds the T cell death rate.
Hence, we can approximate the value of cn that causes the T cell
responses of P1, P4, and P12 to begin expanding around months
2.5, 3, and 2, respectively. We examine this idea more thoroughly
when we introduce the ‘‘optimal load zone’’ for T cell stimulation.
The remaining parameter n, which represents the average
number of T cell divisions per stimulation, is estimated by matching
the results of thesimulation tothe data points. In particular, thepeak
height of the T cell response is a strong indicator of the value of n,
since higher n lead to higher T cell peaks.
To fit the patient-dependent parameters, we convert the data from
[8] into units of concentration, namely thousands of cells per
microliter (k/mL). The data in [8] is originally given in SFCs/well and
10
5 PBMCs were used in each well. However, only a fraction of the
PBMCs are T cells, and measurements of TNF-a and IFN-c in [8]
imply that the standard procedure of measuring the IFN-c response
using the ELISPOT assay may underestimate the strength of a T cell
response. Due to these uncertainties, we assume the measurements
from the ELISPOT assay indicate relative magnitudes among T cell
responses at various timepoints, but we do not convert the SFCs/well
measurements directly into units of concentration (k/mL).
In [8], Chen et al. conducted TNF-a and IFN-c ELISPOT
analyses to measure T cell activity. From this data (in particular
the data of patient P4), it is seen that roughly 4% of CD4+ T cells
and 1% of CD8+ respond to leukemia at the peak of the T cell
response. Hence, we scale the ELISPOT data down by 2500 to
obtain T cell concentrations. This corresponds to about 1% of T
cells from P4 responding to leukemia at the peak of the response.
Furthermore, we use the scaled values for the initial ELISPOT
measurements at time 0 to set the steady state T cell concentration,
sT/dT. The cancer-related parameters are given in Table 1. For
our first study, we assume that there are no resistance mutations,
so we set the mutation rate, u, and the initial concentration of
imatinib-resistant stem cells, z0(0), to 0. The remaining parameters
for each of the three patients are given in Table 6.
Results
Imatinib-Induced Immune Dynamics
Graphs of the solutions of the mathematical model that
correspond to patients P1, P4, P12, along with the measured data
points are displayed in Figure 2. The cases labeled ‘‘no immune
response’’ in Figure 2 are taken from [5] and correspond to setting
the T cell concentrations in Equation 1 to 0, i.e., without the
immune response. In comparison to the no-immune-response
cases, the T cell response contributes to driving the leukemia
population lower than with imatinib alone. Furthermore, the
persistence of anti-leukemia T cells at low levels keeps the
leukemia population from relapsing for up to several years,
whereas in the no-immune-response cases, cancer rebounds are
noticeable after 15 to 24 months (see Figure 2).
We estimate the approximate concentration corresponding to
complete cytogenetic remission, based on [19]. According to [19],
there are 10
12 leukemia cells prior to imatinib treatment. As a
general medical assumption, there are three layers of remission,
hematological, cytogenetic, and molecular, and each layer corre-
sponds to a 2 log, or 100-fold, difference from the previous one.
Hence, hematological remission corresponds to roughly 10
10 cells,
and cytogenetic remission corresponds to roughly 10
8 cells. If the
averagepersonhas6 lofblood,cytogeneticremissioncorrespondsto
a blood concentration of 10
8/6 l=1/60 k/mL. The cytogenetic
remission level is shown as dashed lines in Figure 2.
Regarding the no-immune-response case, Michor et al. demon-
strate that imatinib significantly reduces the populations of
differentiated leukemia cells, but does not eliminate leukemia
stem cells [5]. As a result, the leukemia population decreases
rapidly at the beginning of treatment, while the stem cell
population continues to rise exponentially at a much slower rate
of ry – d0. This phenomenon occurs even in the absence of
resistance mutations, making an eventual relapse unavoidable.
On the other hand, our model including the anti-leukemia T cell
response predicts a substantially slower relapse and provides a fit to
the immunological data. Hence, it is possible that a combination of
imatinib and an immune response keeps the leukemia population
under control and allows patients to remain in cytogenetic remission
for several years. Indeed, the model predicts that the patients remain
in cytogenetic remission beyond month 50.
In all three patients, the leukemia cells are not eliminated
completely by imatinib treatment. In fact, the lowest concentrations
obtained by the cancer populations in Figure 2 for P1, P4, and P12,
are 1.3610
24,7 . 8 610
25, and 2.2610
24 k/mL,respectively, which
correspond to half a million to a million cells remaining in the body,
assuming that an average person has 6 L of blood. As can be
observed in Figure 2C, it seems that leukemia starts increasing again
about 24 months after the start of treatment. This observation
stresses an important point, namely that our model does not predict
that CML is eliminated by imatinib treatment alone. It does,
however, predict that it takes significantly more time for the disease
to relapse (when compared with the Michor model).
Nonetheless, leukemia drops to such a low level that the T cells
are no longer stimulated and begin to contract. As a result, the
immune response does not expand sufficiently to eliminate the
leukemia cells. Unfortunately, although imatinib drives the cancer
population to low levels, it does not eliminate the leukemia stem
cells [5]. Hence, the low population of leukemia stem cells remain
below immune surveillance and out of reach of imatinib, escaping
complete elimination.
In Figure 3 we show simulations for the three patients that
demonstrate what happens when the imatinib treatment is stopped
at month 12. Similar results are observed for all three patients.
The removal of imatinib leads to a resurgence of the leukemia
population which causes an initial increase in the T cell response;
however, the T cell response is never strong enough to overcome
Table 6. The parameters for Figure 2.
Pre-treatment leukemia
loadRy0(0) nd T sT cn
P1 73R7.6610
26 1.2 0.001 1.2610
26 1
P4 23.1R2.4610
26 2.2 0.0022 9610
27 7
P12 116.8R1.2610
25 1.17 0.007 3.08610
25 0.8
For any given dT, sT is chosen such that the steady state T cell concentration, sT/
dT, coincides with the ELISPOT measurement at time 0 (scaled by 2500 as in
Figure 2).
doi:10.1371/journal.pcbi.1000095.t006
Dynamics of the Immune Response to CML
PLoS Computational Biology | www.ploscompbiol.org 6 June 2008 | Volume 4 | Issue 6 | e1000095the rapidly growing leukemia population. This result is consistent
with clinical observations that patients taken off imatinib
invariably relapse [5]. For the purposes of this paper, we assume
that the patients are always treated by imatinib. The strong
immune responses in Figure 3 are induced by imatinib. Indeed, in
the absence of any imatinib treatment, no immune response
initiates, a scenario that is shown in Figure 4.
We would now like to further elaborate on the various aspects
regarding the stimulation of the immune response as reflected in
our model (Equations 1 and 2). From Equation 2, the balance
between immune down-regulation and T cell stimulation by
leukemia cells is given by the term p0e{cnCC. Hence, the optimal
level of T cell stimulation occurs at C=1/cn. We define the optimal
load zone to be the range of leukemic concentrations where the T
cell stimulation rate is faster than the T cell death rate, i.e.,
p0ke{cnCCwdT, where k is the mass-action coefficient and dT is
the T cell death rate. Figure 5 shows the optimal load zones and
stimulus levels of T cells as functions of the leukemia concentra-
tions for the three patients. The anti-leukemia T cell populations
begin expanding when the leukemia concentration drops into the
optimal load zone and begin contracting when the leukemia
concentration drops below the optimal load zone.
Figure 5 shows that if the cancer concentrations grow beyond
approximately 10
1 (for the three patients) the perceived stimulus is
so low that the anti-leukemia T cell response begins to contract,
allowing the cancer population to expand more rapidly. The
expanding cancer population then further suppresses the T cell
response, leading to an uncontrolled relapse. Hence, we can say
that the relapses in Figure 3 are complete, and the immune
responses do not recover.
The level of immune down-regulation, cn, by leukemia cells is a
key parameter that governs how well the immune response can
function against the relapse following the removal of imatinib (see
Figure 3). If cn is high, the leukemia provides less stimulus for the T
cells and passes through the optimal load zone faster during
relapse. This makes it less likely for T cells to be able to multiply to
sufficient levels to hinder the growth of cancer. However, if cn is
low enough, it is possible that the T cells have proliferated enough
during the first imatinib-induced response to stall cancer growth,
provided that imatinib is removed near the time of the T cell peak.
Nonetheless, as we have seen in Figure 4, the immune response
against a relapsing cancer population is expected to be ineffective.
The quantity cn, which varies from patient to patient, measures the
ability of cancer cells to down-regulate the anti-cancer immune
response. It is unknown whether all leukemias exert roughly the
same negative pressure or whether this parameter can vary widely.
A Combined Treatment Strategy
As shown previously at the beginning of treatment, imatinib
causes the leukemia population to drop into the optimal load zone,
Figure 2. Model solutions fit to data measurements for 3 patients. (A) P1, (B) P4, and (C) P12. The measurements of SFCs/well from [8] are
scaled down by 2500 to show relative magnitudes and are shown as black squares. The dashed lines show the approximate level of complete
cytogenetic remission. ‘‘No immune response’’ correspond to the predictions of [5]. ‘‘Leukemia’’ correspond to the results of our model (Equations 1
and 2). The ‘‘T cells’’ curve is obtained with our model after fitting the parameters to the experimental data (shown in blank squares).
doi:10.1371/journal.pcbi.1000095.g002
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treatment, the leukemia population quickly drops below the
optimal load zone, and the T cell population contracts due to lack
of stimulus. A strategy to maintain the leukemia population within
the optimal load zone or to surrogately stimulate anti-leukemia T
cells may help in driving the leukemia population to zero.
The experimental results of [8] suggest that autologous leukemia
cells may be collected from a patient, inactivated, and strategically
reintroduced to enhance the anti-leukemia T cell response. Ideally,
these vaccinations stimulate the immune system enough to drive
the residual leukemia population to zero. We assume that imatinib
is administered throughout the entire course of the therapy.
To study the feasibility of this approach, we introduce
inactivated leukemia cells into our model (Equations 1 and 2).
Inactivated leukemia cells (whose number is denoted by V) die or
decay at a constant rate dV and are supplied into the system in
vaccination boosts at rate sV(t). All leukemia cells may be killed by
interactions with T cells. T cells interacting with leukemia cells
may be stimulated to proliferate or become dead or anergic. These
interactions are also modeled in the same way as in [10]. We
modify the original model by adding Equation 3 and replacing
Equation 2 with Equation 4:
_ V V~{dVV{qCpC ,T ðÞ VzsV T ðÞ , ð3Þ
_ T T~sT{dTT{pC ,T ðÞ CzV ðÞ z2npC nt,Tnt ðÞ qTCntzVnt ðÞ :ð4Þ
Here, V denotes the concentration of inactivated leukemia cells
and Vnt=V(t2nt). We assume that T cells always survive
encounters with inactivated leukemia cells, so that there is no
coefficient qT before the variable Vnt in Equation 4.
The leukemia cells used in vaccinations can be inactivated via
irradiation. Since they are in the process of dying, we estimate that
they do not survive much longer than 24 to 72 hours, so we set the
decay rate dV=0.35, which corresponds to a half life of 2 days.
The supply rate sV(t) of inactivated leukemia cells will be 0 except
when the vaccination is being delivered. During vaccination, we
estimate that a total quantity qV of inactivated leukemia cells is
delivered at rate 100qV for a duration of 0.01 days, which is slightly
under 15 minutes. The parameters related to inactivated leukemia
cells are given in Table 7.
Since it is unclear how many vaccinations will be required to
eliminate the cancer, we will optimize the treatment strategy
according to the following method:
1. Imatinib. Begin imatinib treatment at time 0 and continue
treatment throughout immunotherapy.
2. Timing. For a given dosage, assume that there is only one
vaccination and find the optimal timing such that the resulting
minimum cancer concentration is as low as possible. This will
determine the timing of the first vaccination.
3. Pacing. Continue delivering vaccinations of the same dosage
at fixed time intervals until eliminating leukemia (according to
the elimination criterion Equation 5, defined below).
Figure 3. A predicted relapse when imatinib is removed at month 12. The T cell response is never sufficient without imatinib and the
removal of imatinib leads to full relapse. (A) P1. (B) P4. (C) P12.
doi:10.1371/journal.pcbi.1000095.g003
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minimum leukemia concentration with the fewest vaccinations. We
implement this optimization strategy, because it is more efficient than
attempting to globally optimizeseveral vaccinations of varying dosage
and irregular time intervals at once. Indeed, it is a one-dimensional
searchproblem, as opposed toa higher dimensional problem. For this
assessment, we also assume that there are no mutations, i.e. u=0.
Results of relaxing this assumption are discussed below.
We numerically solve the system given by Equations 2–4 using
the DDE solver ‘dde23’ from Matlab 7.0. For each run, we
evaluate the solution up to day 400. We use parameter sets from
Table 6 and examine vaccination dosages of 0.1 to 1 k/mL.
For each fixed dosage, we find optimal vaccination delivery
times (up to a day), and our goal is to drive the cancer below
1 cell/6 L,10
210 k/mL, i.e.
Total cancer concentrationv10{10k
 
mL: ð5Þ
We assume that the criterion (Equation 5) represents cancer
elimination. Since this model is a continuous deterministic system,
in reality, Equation 2 never allows the cancer population to
actually reach 0.
Using the aforementioned method of optimization, we optimize
the timing of a series of vaccinations of varying dosages. We
measure dosages in units of concentration (k/mL), referring to
the average concentration of inactivated leukemia cells in the
patient’s body. Since the average person has about 6 L of blood, a
vaccination of 1 k/mL corresponds to 6610
9 inactivated leukemia
cells. For the parameters from Table 6 corresponding to P4,
the optimal delivery times and minimum cancer concentrations
for up to five vaccinations of varying dosages are given in
Table 8.
On one hand, five vaccinations of dosage 0.1 k/mL can
eliminate cancer in P4. On the other extreme, one vaccination
of dosage 1.0 k/mL works as well. Depending on whether it is more
important to eliminate cancer as fast as possible or to minimize the
total dosage of irradiated cancer cells, different strategies may be
preferable. Also, it may be advantageous to vary vaccination
dosages over time and consider dosages below 0.1 k/mL, but a
thorough analysis of this optimization problem lies beyond the
scope of this paper.
The time evolution of the cancer and T cell populations for the
treatment strategy in row 1 of Table 8 are shown in Figure 6.
Repeated stimulation of T cells by the five vaccinations causes the
T cell level to multiply to over 10 times the T cell peak with
imatinib alone in Figure 2B. As a result, the leukemia population is
completely eliminated.
In addition, analogous tables of vaccination strategies for P1 and
P12 are shown in Tables 9 and 10. The T cells of P1 and P12 seem
to be less responsive than those of P4, since they require higher
dosages to eliminate the leukemia cells.
In all cases, the first vaccinations are given before the peak of
the T cell responses to boost the response. The peaks of the T cell
populations fall between months 9 and 10 (see Figure 2), and in all
cases, the first vaccinations fall around months 7 to 8. It is optimal
Figure 4. Solving the model equations without an imatinib treatment. The T cell responses are fully suppressed and stay flat at their steady
state concentrations while cancer grows rapidly. (A) P1. (B) P4. (C) P12.
doi:10.1371/journal.pcbi.1000095.g004
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contract.
Thereafter, the following vaccinations serve to sustain the
immune response over an extended time, so the gaps between
these vaccinations depend on how long it takes for the previous
vaccination to clear out of the system.
In the data of [8] there were 2 patients with no detectable
immune response (P10 and P14). The leading hypothesis there was
that the immune response was present but that it was below the
detection level. In the mathematical model, low-level immune
responses can be obtained when immune down-regulation from
leukemic cells is high or when T cell division is low. In these cases,
vaccinations still boost the immune response and eliminate
leukemia, but dosages must be higher or they must be
administered for longer periods. In addition, if the level of
immune down-regulation from leukemia cells is very high, the
timing of the first vaccination will be much later than for P1, P4,
Figure 5. Stimulation levels of anti-leukemia T cells versus logs of the cancer concentrations. Optimal loads are the cancer
concentrations C for which the perceived stimulus, p0e{cnCC, is maximized. Optimal load zones are the range of leukemic concentrations where the T
cell stimulation rate is faster than the T cell death rate, i.e. p0ke{cnCCwdT. (A) P1. (B) P4. (C) P12.
doi:10.1371/journal.pcbi.1000095.g005
Table 7. Parameter estimates for inactivated leukemia cells.
Parameter Description Estimate
V(0) Presumably vaccinations begin
after time 0
dV Decay rate of inactivated
leukemia cells
0.35/day
qV Vaccination dosage To be optimized
tV Duration of delivery 0.01 day
sV Vaccination supply rate qV=tV t[ Ti,TiztV ½ 
0 otherwise
 
where Ti
are vaccination delivery times
doi:10.1371/journal.pcbi.1000095.t007
Table 8. Vaccination strategies for P4.
Dose (k/mL), number
of cells Timing Pacing Number
log10 [Min
cancer load]
0.1, 6.0610
8 233 10 5 210.5
1.0, 6.0610
9 240 - 1 210.4
For each dosage, the timing indicates the day on which the first vaccination is
given, and the Pacing indicates the number of days between subsequent
vaccinations. The Number indicates the number of vaccinations administered,
and the final column indicates the base 10 logarithm of the minimum cancer
concentration attained after the final vaccination. Values of less than 10
210
correspond to fewer than one cell in the body and denote cancer elimination.
doi:10.1371/journal.pcbi.1000095.t008
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pass into the optimal load zone. Because these immune responses
are too low to detect using ELISPOT, we do not have data points
to fit the model. Hence, any vaccination strategy for P10, P14, or
any of the other patients with no detectable response will be highly
speculative. For such patients we forgo any quantitative conclu-
sions and instead state that strategic vaccinations are likely to
enhance any anti-leukemia T cell response, even when the anti-
leukemia response is low.
Importance of Timing and Pacing
The timing and pacing of the vaccination strategies are critical
to the success of the outcome. For example, consider the
alternative vaccination strategies in Tables 11, 12, and 13. These
are deviations from the optimized vaccination strategies in
Tables 8, 9, and 10, respectively.
Note that if vaccinations are initiated within 30 days of the start
of imatinib treatment, the effect of the vaccinations is insignificant.
There is hardly any anti-leukemia immune response, and the
decline in the leukemia population is mainly due to natural death
under imatinib. This happens since within the first 30 days, the
leukemia population is still well above the optimal load zone, and
in general, vaccinations are ineffective when the leukemic load is
above the optimal load zone (where the immune suppression is too
strong). However, once the leukemic population is sufficiently low,
the optimal load is no longer an issue, since inactivated leukemic
cells that have no immunosuppressive effects are used for
vaccinations.
On the other hand, administering vaccinations too late (e.g. at
300 days) is not entirely ineffective, since leukemia has already
passed into remission and no longer exerts a great immuno-
suppressive effect. However, 300 days after the start of treatment,
the initial anti-leukemia T cell response has started to decline, so
the response to vaccination is not as strong. By considering early
and late vaccinations, we see that optimizing vaccination delivery
times depends on a balance between minimizing the immuno-
suppressive effect of leukemia and maximizing the available anti-
leukemia T cells to respond to the stimulus.
Figure 6. The treatment strategy in row 1 of Table 8. (A) Time evolution of cancer and T cell populations. Vaccinations are delivered on days
233, 243, 253, 263, and 273. (B) Time evolution of the four types of leukemia cells: stem cells (SC), progenitors (PC), differentiated cells (DC), and
terminally differentiated cells (TC). Concentrations are shown on a logarithmic scale.
doi:10.1371/journal.pcbi.1000095.g006
Table 9. Vaccination strategies for P1.
Dose (k/mL), number
of cells Timing Pacing Number
log10 [Min
cancer load]
0.1, 6.0610
8 202 5 12 210.7
2.3, 6.0610
10 209 - 1 210.2
doi:10.1371/journal.pcbi.1000095.t009
Table 10. Vaccination strategies for P12.
Dose (k/mL), number
of cells Timing Pacing Number
log10 [Min
cancer load]
0.1, 6.0610
8 195 4 11 210.1
2.0, 1.2610
10 199 - 1 210.4
doi:10.1371/journal.pcbi.1000095.t010
Table 11. Alternative vaccination strategies for P1.
Dose (k/mL), number
of cells Timing Pacing Number
log10 [Min
cancer load]
0.1, 6.0610
8 1–30 5 12 23.3
300 5 12 26.2
233 1 12 28.0
233 20 12 25.4
2.3, 1.4610
10 1–30 - 1 23.3
300 - 1 27.3
doi:10.1371/journal.pcbi.1000095.t011
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optimalpacingbetweenvaccinationsthatwilloptimallymaintainthe
immune stimulation over time. As we can see from Tables 11–13,
excessively low and high intervals of 1 and 20 days lead to less
effective vaccination strategies. Hence, by fitting patient data and
modeling various vaccination strategies, we can predict the most
effective ways to utilize the available resources for a maximal impact.
Overloading Vaccination Strategies and Sensitivity to dT,
cn, and n
In general, the vaccination strategies for each patient will still
work if T cells die at slower rates, if the immune-suppression is
lower, or if T cells divide more after stimulation. These scenarios
correspond to decreasing dT, decreasing cn, and increasing n.I n
these cases, the vaccination strategies should not only continue to
work, but should also become more effective.
However, our optimization strategy seeks to find the lowest
dosage or smallest number of vaccinations necessary to eliminate
cancer. Hence, these strategies are sensitive to underestimates of
dT, underestimates of cn, and overestimates of n. To allow a buffer
for a more robust vaccination plan, we can develop an optimal
strategy for overloading the optimal vaccination strategies. For
example, we can give P4 one vaccination of dosage 2.0 k/mL
rather than 1.0 k/mL. Alternatively, we can give P4 10 vaccinations
of dosage 0.1 k/mL instead of 5 vaccinations. This will allow the
vaccinations to be much more reliable and robust to errors in the
parameter estimates.
A full treatment on the optimal way to overload a vaccination
strategy leads to more complex optimization problems, which we
leave for future work. However, in Tables 14–16, we consider the
effect of doubling the vaccination dosages or the number of
vaccinations for P1, P4, and P12. For each overloaded vaccination
strategy, we report the amount that cn and n can vary from their
original values without rendering the strategy ineffective. For
convenience, variabilities are reported as 6 (some percentage), but
in reality, these variabilities only correspond to upper bounds for cn
and lower bounds of n. Since the parameter dT is more readily
measured from T cell decay rates, we exclude it from the
sensitivity analysis.
From this preliminary analysis, it appears that doubling is more
effective for strategies consisting of vaccine low dosages adminis-
tered multiple times. It is unclear whether it is more effective to
double the dosages or to double the number of times vaccinations
are administered, since the relative efficacies of each approach
vary from patient to patient. In any case, overloading vaccinations
seems to be an effective method for increasing the robustness of
vaccination strategies against uncertainties in parameter values.
Sensitivity Analysis
The analysis in the previous sections focused on three particular
patients and proposed three different treatment strategies for each
case. However, to extend out findings to a general approach, we
would like to examine which scenarios favor one vaccination
regime over another. Indeed, from Tables 8–10, we notice that
patient P4 requires a much lower vaccination dosage than patients
P1 and P12 to obtain an adequate immune response. This
observation implies that the immune response of P4 is more active
than the immune response of P1 and P12. We would thus like to
understand which measurable parameters and initial conditions
Table 12. Alternative vaccination strategies for P4.
Dose (k/mL), number
of cells Timing Pacing Number
log10 [Min
cancer load]
0.1, 6.0610
8 1–30 10 5 23.2
300 10 5 27.6
233 1 5 26.7
233 20 5 29.4
1.0, 1.2610
10 1–30 - 1 23.2
300 - 1 28.6
doi:10.1371/journal.pcbi.1000095.t012
Table 13. Alternative vaccination strategies for P12.
Dose (k/mL), number
of cells Timing Pacing Number
log10 [Min
cancer load]
0.1, 6.0610
8 1–30 4 11 23.1
300 4 11 25.9
195 1 11 28.3
195 20 11 25.9
2.0, 1.2610
10 1–30 - 1 23.1
300 - 1 26.7
doi:10.1371/journal.pcbi.1000095.t013 Table 14. Overloaded vaccination strategies for P1.
Dose (k/mL) Timing Pacing Number
Allowed variability
for cn and n
260.1 202 5 12 610%
0.1 202 5 2612 610%
262.3 209 - 1 64%
doi:10.1371/journal.pcbi.1000095.t014
Table 15. Overloaded vaccination strategies for P4.
Dose (k/mL) Timing Pacing Number
Allowed variability
for cn and n
260.1 233 10 5 610%
0.1 233 10 265 612%
261.0 240 - 1 65%
doi:10.1371/journal.pcbi.1000095.t015
Table 16. Overloaded vaccination strategies for P12.
Dose (k/mL) Timing Pacing Number
Allowed variability
for cn and n
260.1 195 4 11 67%
0.1 195 4 2611 68%
262.0 199 - 1 64%
doi:10.1371/journal.pcbi.1000095.t016
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Furthermore, we would like to understand how the treatment
strategies can be adapted to the individual patients based on the
measured strength of their immune responses.
To study the correlation between parameters and the effectiveness
of proposed vaccination strategies, we apply the Latin Hypercube
sampling (LHS) method [20]. This method provides means of
simultaneously sampling a wide range of dynamical parameters and
is useful for statistically determining which parameters correlate
highly to certain desired outcomes. LHS involves numerically
simulating the model multiple times with randomly sampled sets of
parameters.Thesamplesarechosensuchthateachparameteriswell
distributed over its range of possible values.
For each LHS simulation, we test one vaccination strategy over
a range of 500 randomly sampled parameter sets. The parameters
are sampled uniformly over the ranges indicated in Table 17. As
indicated in the table, we vary every parameter and initial
condition except the decay rate of dead cancer cells (which are
used only in vaccinations).
From Tables 8–10, we see that the optimal start times for our
vaccination strategies are between around 200 and 240.
Furthermore, the optimal pacing between vaccinations is between
around 5 and 10 days. Using these numbers as guides, we test
several variations of vaccination strategies with start times at either
200 or 240 days and pacings of 5, 10, 20, or 40 days. Furthermore,
we try vaccination dosages of 0.1 and 0.2 k/mL. The results are
shown in Table 18. In this table, alongside the tested vaccination
strategies, we include the fraction of 500 LHS samples that result
in cancer elimination. The first eight strategies consist of five
vaccinations with dosage 0.1 k/mL. Hence, these strategies require
a total dosage of 0.5 k/mL. If we assume that the average person
has 6 L of blood, this total dosage corresponds to 0.5 k/
mL66610
6 mL=3 610
9 leukemia cells.
Among these first eight vaccination strategies with a total dosage
of 0.5 k/mL, we see that vaccination strategies that start on day 240
are more effective than those that start earlier on day 200. In
addition, it seems that a pacing of 20 days between vaccinations
performs better than the alternative pacings of 5, 10, and 40 days.
Observing the trend in the eight tested strategies, it seems that the
optimal pacing would fall between 10 and 40 days.
Among the ten strategies with total dosage 1.0 k/mL, it seems
again that starting vaccinations on day 240 is better than starting
Table 17. Parameter ranges to be used for Latin Hypercube sampling.
Description Estimate Range PPMC SROC
l fractional adjustment constant 0.75 0.5 to 1 20.2152 20.1395
d0 SC death rate 0.003 l/day 625% 20.0354 20.0123
d1 PC death rate 0.008l 625% 20.0643 20.0066
d2 DC death rate 0.05l 625% 20.1497 20.0130
d3 TC death rate l 625% 0.0206 0.0080
ry Growth rate for nonresistant cells without imatinib treatment 0.008/day 625% 0.0242 0.0174
ay 1.6 625% 20.0366 20.0259
by 10 625% 0.0372 0.0087
cy 100 625% 0.0419 0.0411
a0
y Rates during imatinib treatment ay/100 Same as ay/100 - -
b0
y by/750 Same as by/750 - -
c0
y cy Same as cy --
rz Growth rate for resistant cells 0.023/day 625% 0.0036 0.0158
az ay Same as ay --
az by Same as by --
cz cy Same as cy --
u Mutation rate per division 4610
28/division 6100% 20.0156 0.0252
k Kinetic coefficient 1(k/mL)
21 day
21 625% 20.1241 20.1287
p0 Prob. T cell engages cancer cell 0.8 625% 20.1328 20.1606
qC Prob. cancer cell dies from encounter 0.75 625% 0.0084 0.0105
qT Prob. T cell survives encounter 0.5 625% 20.0947 20.1419
t Duration of one T cell division 1 day 12–24 hrs 0.0676 0.0301
N Avg no. of cell divisions 1.17 to 2.2 1 to 3 20.4681 20.6889
dT T cell death rate 1–7610
23/day 1E-3 to 1E-2 0.1786 0.2523
dV Inactivated leukemia cell decay rate 0.35/day Not varied - -
sT T cell supply rate 1E-5 to 1E-6 k/mL/day 1E-5 to 1E-6 20.0412 20.0557
cn Decay rate of immune responsivity 0.8 to 7/day 0 to 10 0.1785 0.2623
C(0) Pre-treatment cancer load 23.1–116.8 k/mL 20 to 200 0.1819 0.0717
Also, shown are correlations between parameters and minimum cancer concentrations. Correlation coefficients are as follows: Pearson product-moment correlation
(PPMC), Spearman rank-order correlation (SROC).
doi:10.1371/journal.pcbi.1000095.t017
Dynamics of the Immune Response to CML
PLoS Computational Biology | www.ploscompbiol.org 13 June 2008 | Volume 4 | Issue 6 | e1000095too early on day 200. Furthermore, it seems that spreading the
vaccinations out among ten small doses is more effective than
grouping them into five larger doses or one very large dose.
In this work we only examined a limited set of possible
vaccination strategies. Indeed, there is no reason to require that all
vaccinations will be of the same size or that the pacing will remain
uniform. However, generalizing our survey of possible strategies
poses a challenging optimization problem that is beyond the scope
of the current paper.
On the other hand, LHS sampling allows us to determine the
statistical correlations between the treatment outcomes and a wide
range of model parameters. For each LHS simulation, we measure
the correlations between the varied parameters and two indices:
the minimum cancer concentration attained during the course of
simulation (600 days) and the success of the treatment strategy. For
our correlations, we use the Pearson and Spearman rank-order
coefficients, and consider a treatment to be successful if it causes
the cancer concentration to drop below 10
210 k/mL, which is
approximately the concentration of half a cancer cell in the blood.
In Table 17, we show the Pearson and Spearman rank-order
coefficients for the fifth vaccine with total dosage 0.1 k/mL. (This is
the strategy with dosage 0.1 k/mL per vaccination with vaccinations
scheduled every 10 days between day 240 and 330). Figure 7 shows
scatter plots of simulation results for this vaccination strategy with
respect to (dT, n)a n d( cn, l). The correlations obtained from all other
tested strategies are comparable.
We see from the correlation table that the most sensitive
parameter is the average number of T cell divisions per
stimulation, n. This result makes sense because n is a direct
measurement of the inclination of T cells to proliferate. More
responsive T cells will perform much better under vaccinations.
This observation implies that the T cell activity of a patient, and
especially its inclination to proliferate, should be measured
(probably in vitro) before and during the imatinib treatment to
gauge the intensity of the vaccination treatment that is needed to
ensure sufficient T cell expansion.
There are three additional parameters that have some influence
on the outcome. These are the T cell death rate, dT, the level of
immune downregulation, cn, and the fractional adjustment
constant for cancer death rates, l. The T cell death rate is
relevant, because T cells that die faster require a prolonged
stimulation to remain at effective levels. This is one reason why
spreading vaccinations out across many smaller doses seems
largely more effective than combining vaccinations into larger
doses. The latter strategy would only be preferable if the average T
cell death rate is low enough to allow the T cell response to persist
for a long time without stimulus. The parameter l directly affects
the time it takes for cancer to enter remission. If l is low, it means
that imatinib is less effective, so it takes longer for a patient to enter
remission. Furthermore, the level of immune downregulation, cn,
affects the time that downregulation becomes low enough to make
the vaccinations effective. The combined effects of l and cn affect
the optimal start time of vaccination treatment. Low l and high cn
would require the start time of the vaccination to be postponed
until downregulatory effects have diminished. While it may be
difficult to measure these parameters directly, the ambient level of
immune downregulation can be deduced by tracking T cell
activity during the course of imatinib treatment.
All the parameters other than the four discussed above have
little influence on the outcome of the treatment. We especially
point out that the mutation rate per cell division, u, and the initial
leukemia load, C(0), are among the irrelevant parameters. While
the initial loads will vary by at most a factor of three or so,
remission time is much more strongly affected by the exponential
decay rate of cancer under imatinib, which pertains more to the
parameter l than anything else. Ultimately, the sensitivity analysis
shows that n, which measures the T cell responsivity upon
stimulation, is the key parameter to predicting the effectiveness of
Table 18. Tested vaccination strategies and fraction of LHS samples that result in successful treatments.
Total dosage (k/mL) Dosage (k/mL) Schedule (Number of successes)/500
0.5 0.1 200, 205, 210, 215, 220 0.474
0.1 200, 210, 220, 230, 240 0.490
0.1 200, 220, 240, 260, 280 0.502
0.1 200, 240, 280, 320, 360 0.488
0.1 240, 245, 250, 255, 260 0.510
0.1 240, 250, 260, 270, 280 0.514
0.1 240, 260, 280, 300, 320 0.520
0.1 240, 280, 320, 360, 400 0.472
1.0 0.1 200, 205, 210, 215, 220, 225, 230, 235, 240, 245 0.578
0.1 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 0.622
0.1 200, 220, 240, 260, 280, 300, 320, 340, 360, 380 0.610
0.1 240, 245, 250, 255, 260, 265, 270, 275, 280, 285 0.630
0.1 240, 250, 260, 270, 280, 290, 300, 310, 320, 330 0.642
0.1 240, 260, 280, 300, 320, 340, 360, 380, 400, 420 0.616
0.1 200, 210, 220, 230, 240 0.570
0.1 240, 250, 260, 270, 280 0.624
0.1 200 0.482
0.1 240 0.532
(Assuming the average person has 6 L of blood, the total number of leukemia cells needed for each vaccination strategy is (Total dosage)66610
6 mL).
doi:10.1371/journal.pcbi.1000095.t018
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dynamical parameters can be measured in vitro before and during
the course of treatment to devise or adjust a vaccination strategy to
optimize anti-leukemia T cell stimulation.
Discussion
Among all mathematical models of CML, our approach is
unique in the sense that the experimentally observed anti-leukemia
immune response is incorporated into the model. With the
addition of the T cell response in our model, persistence of anti-
leukemia T cells even at low levels seems to prevent the leukemia
from relapsing (for at least 50 months). We therefore hypothesize
that anti-leukemia T cells responses may help maintain remission
under imatinib therapy. Therapy with imatinib (and other
targeted therapies being developed) has the advantage to target
leukemic cells more selectively than non-specific therapies such as
chemotherapy and radiation. As such, host immune function,
including antigen presentation, may be restored more rapidly than
after chemotherapy, due to alleviation of leukemia-induced
immune suppression. Importantly, normalization of host immune
function, while leukemia antigens are still present, may optimally
drive anti-leukemia immune responses.
Our model suggests that the balance between immune down-
regulation and T cell stimulation by leukemic cells determines the
effectiveness of the anti-leukemia T cell response. Studying the
optimal level of stimulation led us to define the novel concept of an
‘‘optimal load zone’’ as the range of leukemic cell concentrations
where the T cell stimulation rate is optimal. In general, imatinib
causes the leukemic cell population to fall into the optimal load
zone, stimulating a T cell response most efficiently and to the
highest amount before it drops out of this zone. At a certain
threshold below the optimal load zone, leukemic cells become
essentially invisible to T cells due to low interaction rates, and the
immune response contracts. At this point, one would need
exogenous stimulation to maintain T cell proliferation.
This led us to hypothesize that cryopreserved autologous
leukemic cells, inactivated by irradiation, may be given to patients
in remission as vaccines to enhance T cells responses. To study this
approach, we added inactivated leukemic cells (unable to
proliferate or exert immune suppression) to our model. A strategy
of immunotherapy and imatinib treatment for each patient was
constructed using an optimization algorithm. Our model predicts
that the timing and pacing of the vaccinations are crucial.
Although vaccination optimizations are presented for particular
patients, it may be possible to devise a more general strategy that
works most of the time. Furthermore, the parameter fitting can be
more refined to consider several likely parameter sets, and the
optimization problem can be expanded to consider variable
vaccination dosages qV,1, qV,2,…, qV,n under the constraint P
qv,i~constant.
Another question is whether the effects of vaccination can be
clinically observed. Since most leukemia patients taking imatinib
undergo cytogenetic remission, but not molecular remission
(P.P.L., unpublished data), it is possible to observe whether
vaccinations can further drive the leukemia to molecular
remission. The thresholds for cytogenetic and molecular remission
are 10
8 and 10
6 leukemia cells in the body, respectively. Assuming
that an average person has 6 L of blood, these counts correspond
to leukemia concentrations around 10
22 and 10
24 k/mL,
respectively. Thus, the model predicts that a series of vaccinations
will not only drive the leukemia population below the molecular
remission level, but will actually drive it to extinction.
To clinically implement these treatments, one would also need
to have a criterion for starting the vaccinations. From the model,
we observed that vaccinations are best administered just prior to
the peak of the T cell response; however, in practice, it may be
hard to determine the T cell peak times. We observe that for all
patients, the T cell peaks occurred around 10 months after starting
the imatinib treatment, while they entered complete and major
cytogenetic remissions a few months earlier. Determining whether
there is a correlation between remission times and T cell peak
times will prove useful in carrying out treatments, and may be the
goal of future studies. Such a study would require simultaneously
measuring the T cell and the leukemia levels over time, perhaps at
the molecular level.
An important issue is whether stem cells are immunologically
privileged. In principle, T cells are known to have the capacity of
killing leukemia stem cells as evidenced by the success of allogeneic
bone marrow transplants. It is unknown whether the autologous
immune response can produce similar results. It is also possible
Figure 7. A sensitivity study. (A) Scatter plot of LHS simulation results with respect to the T cell death rate, dT, and the average number of T cell
divisions upon stimulation, n. As apparent from the figure, the treatment outcomes are highly correlated to the values of n. (B) Scatter plot of LHS
simulation results with respect to the immune downregulation, cn, and the fraction adjustment for cancer death rates, l.
doi:10.1371/journal.pcbi.1000095.g007
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anti-leukemia T cells. However, this rate is probably much slower
than the rate of acquiring imatinib resistance. In any case, even if
stem cells or mutated leukemia cells were immunologically
privileged, what we propose may still substantially delay the
leukemia relapse. Indeed, [21] and [22] show that an active
immune response in conjunction with imatinib plays a significant
role in the elimination of leukemia. These papers describe
experiments in which imatinib was given to CML patients who
relapsed after allogenic bone marrow transplants, resulting in
sustained remission.
We also observe that the more demanding vaccination strategies
for each patient P1, P4, and P12 require total doses of 2.3 k/mL,
1.0 k/mL, and 2.0 k/mL, respectively. These samples can be
obtained from 6 L62.3/73=190 mL,6 L 61.0/23.1=160 mL,
6L 62.0/116.8=100 mL of pre-treatment blood from P1, P4,
and P12, respectively. Since we are only interested in collecting
leukemia cells prior to imatinib treatment, these samples can be
gathered by filtering the white blood cell component of the
patient’s blood. For reference, we point out that one US pint is
about 500 ml, and this quantity of whole blood is routinely
collected from healthy individuals.
An issue that was not investigated directly in this study is the
functional form of immune downregulation. In our model, we
chose to use the form e{cnC, i.e., an exponential decay. It will be
difficult to conduct a sensitivity analysis with respect to the
function form. However, as implied by the previous discussion, the
functional form does not greatly affect outcome of vaccination
strategies as long as there is very low residual downregulation after
cancer remission. In other words, when leukemia drops below
remission, immune cells are no longer effectively downregulated.
Since downregulation is usually hypothesized to be the result of
contact-dependent mechanisms or suppression by negative
cytokine signaling, it follows that the effects of downregulation
will most likely disappear or at least become greatly reduced once
the source of downregulation is removed.
As a final point, we note that in the Michor model leukemia
relapses at 15 to 24 months despite continued imatinib therapy
with the Michor model [5]. This results from imatinib’s inability to
control leukemic stem cells - a conclusion of this previous work [5].
However, this contradicts clinical observations in imatinib-treated
patients [23], who generally remain in remission well beyond 30–
40 months. With the addition of the T cell response in our model,
persistence of anti-leukemia T cells even at low levels prevented
leukemia from relapsing for up to 50 months. We therefore
hypothesize that anti-leukemia T cell responses may help maintain
remission under imatinib therapy. Therapy with imatinib (and
other targeted therapies being developed) has the advantage to
target leukemic cells more selectively than non-specific therapies
such as chemotherapy and radiation [24]. As such, host immune
function may be restored more rapidly than after chemotherapy,
due to alleviation of leukemia-induced immune suppression.
Importantly, normalization of host immune function, while
leukemia antigens are still present, may optimally drive anti-
leukemia immune responses. It should be noted that imatinib was
shown to have some immunomodulatory activity in a mouse
arthritis model [25].
An alternative model of CML dynamics was recently published
by Roeder et al. [6]. In this model, stem cells exist in non-
proliferating or proliferating states. The likelihood for a stem cell
to proliferate and differentiate or to return to dormancy is
determined by an internal mechanism, called the affinity function.
After imatinib treatment, which in this model can target
proliferating but not non-proliferating stem cells, most remaining
stem cells are dormant, resulting in a much longer remission and a
slower relapse than the Michor model [5]. In view of our present
work, it is important to note that the model in [6] does not include
the immune response. However, quantitative data for the non-
proliferating or proliferating states are not available. In either case,
the models do not significantly diverge for the first few years and
our analysis focuses within this time period when the anti-leukemia
immune response is still active. Hence, the anti-leukemia immune
response that we observed experimentally and modeled is
consistent with both models.
Conclusions
The approach presented in this paper accounts for the role of
the anti-leukemia specific immune response in the dynamics of
CML. By combining experimental data and mathematical models
we demonstrate that persistence of anti-leukemia T cells even at
low levels seems to prevent the leukemia from relapsing (for at least
50 months). Consequently, we hypothesize that anti-leukemia T
cells responses may help maintain remission under imatinib
therapy.
The mathematical model together with the experimental data of
[8] imply that there may be a feasible, low risk, clinical approach
to enhancing the effects of imatinib treatment. These conclusions
rest on the hypotheses that imatinib induces an innate immune
response and that the patient’s immune system functions alongside
imatinib to sustain cytogenetic remission for up to several years.
The mathematical modeling of experimental data provides
insights, suggesting that these responses may play a critical role in
maintaining remission. Our model suggests that properly timed
vaccinations with autologous leukemic cells, in combination with
imatinib, can sustain the T cell response and potentially eradicate
leukemic cells. It also shows that vaccinations must be optimally
timed in relation to host anti-leukemia T cell responses. A key
assumption in the model is that anti-leukemia T cells can target all
leukemic cells (including stem cells and cells that develop resistance
to imatinib). Such an assumption is supported by the graft-versus-
leukemia response of allogeneic stem cell transplantation [26,27]
suggesting that leukemic stem cells can be eliminated by the
immune response. Resistance to imatinib, such as via abl
mutations, could render a leukemic cell even more susceptible to
immune targeting. Even if this is not the case, the proposed
therapeutic strategy could still potentially result with a substantial
increase of the expected time to a relapse. Combining imatinib
with optimally timed vaccinations could lead to a potential cure of
CML. While cancer vaccines is not a new concept, the importance
of optimal timing of vaccinations in relation to the underlying
endogenous immune response (which the vaccine attempts to
boost) is novel and not previously suggested in the field of cancer
immunotherapy. This approach may be transferable to other
cancers, as other molecular targeted therapies become available.
While it is still too early to begin human clinical trials with our
novel immunotherapy strategies, our immediate goal is to refine
and validate our model predictions with additional patient
measurements, and only then propose a clinical trial. There is
still no good animal model of CML to validate our model
predictions or test various vaccination conditions. As such, we are
continuing to analyze samples from additional patients - at higher
resolution time points guided by our results thus far. We will
particularly focus on patients that relapse on imatinib to study
their immune responses before, during, and after the relapse
period. Such patients are now being put on next generation
molecular targeted drugs such as dasatinib, which will bring 80%
of patients with imatinib-resistant leukemia back into remission.
We will analyze the immune responses in these patients. At all time
Dynamics of the Immune Response to CML
PLoS Computational Biology | www.ploscompbiol.org 16 June 2008 | Volume 4 | Issue 6 | e1000095points, we will obtain accurate measurements of the leukemia load
via real-time PCR. This will allow us to validate our predictions
for the optimal load zone.
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